Sean Anthony Eddy/E+ via Getty Images Roche (OTCQX:RHHBY)(OTCQX:RHHBF)(OTCPK:RHHVF) still has good long-term prospects since the last time I wrote an article about it. This was with respect to an article entitled “Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender”. In this article, I noted that this company had good long-term value with…
JazzIRT/iStock via Getty Images Monte Rosa Therapeutics (NASDAQ:GLUE) has been making good progress in advancing its pipeline of molecular glue degraders [MGDs]. The goal is to have protein-to-protein interaction to eliminate diseases but without binding pockets. Such an approach allows it to go after target indications that are thought to be undruggable with other small…
AzmanJaka Listen below or on the go on Apple Podcasts and Spotify Roche (OTCQX:RHHBY) to acquire Telavant (ROIV) (PFE) for $7.1B, adds new bowel disease therapy to pipeline. (00:22) Stonepeak agrees to buy shipping-container firm Textainer (TGH) for $50/share (update). (01:23) Japan antitrust watchdog to investigate Google (GOOG) (GOOGL) over search dominance – report. (02:32)…
As a result of the $7.1 billion transaction, Roche will get the rights to develop and distribute RVT-3101 in the US and Japan. The deal is expected to be completed at the end of this year or in the first quarter of 2024. Swiss healthcare giant F. Hoffmann-La Roche AG, commonly known as Roche Holding AG (SWX: RO),…
CatEyePerspective/iStock via Getty Images Roche’s (OTCQX:RHHBY) stock price has declined from a peak of CHF 385 in April 2022 to CHF 250 today, underperforming its peers and the broad equity market. Roche relied heavily on three blockbusters (namely Avastin, Herceptin and Rituxan, also called AHR). Before losing their patent protections between 2018 and 2020, these…